MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hep.0000000000001385

Медицинская библиотека · Hepatology (Baltimore, Md.) · 2025

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.

Lau George, Sangro Bruno, Cheng Ann-Lii, Kudo Masatoshi, Kelley Robin Kate, Tak Won Young, Gasbarrini Antonio, Reig Maria, Lim Ho Yeong, Tougeron David, De Toni Enrico N, Tam Vincent C, Mody Kabir, Gong Jun, Crysler Oxana V, Sukeepaisarnjaroen Wattana, Lipatov Oleg, Morimoto Manabu, Archambeaud Isabelle, Burgio Valentina, Phuong Le Thi Tuyet, Chao Yee, Peron Jean-Marie, Berres Marie-Luise, Ko Yoo-Joung, Ran Di, Makowsky Mallory, Negro Alejandra, Abou-Alfa Ghassan K

СтатьяКлиническое исследование III фазыРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIMS: In the global phase III HIMALAYA study in unresectable HCC, STRIDE significantly improved overall survival (OS) versus sorafenib; durvalumab was noninferior to sorafenib. Immune checkpoint inhibitor studies have shown an association between the occurrence of immune-mediated adverse events (imAEs) and improved OS. We assessed potential associations between the occurrence of imAEs and OS, and temporal patterns of imAEs, in HIMALAYA.

APPROACH AND

RESULTS

OS in participants who did and did not experience imAEs and the frequency and timing of imAEs were assessed for STRIDE and durvalumab in the safety analysis set of HIMALAYA. imAEs occurred in 139/388 (35.8%) and 64/388 (16.5%) participants with STRIDE and durvalumab, respectively; most were low grade. OS HRs (95% CI) in participants who experienced imAEs versus those who did not were 0.73 (0.56-0.95) for STRIDE and 1.14 (0.82-1.57) for durvalumab. The 36-month OS rate (95% CI) for STRIDE was 36.2% (28.1-46.7) and 27.7% (22.4-34.2) in participants who did and did not experience imAEs, respectively. The most common imAE category with STRIDE was endocrine events (16.5%). Most imAEs occurred ≤3 months after treatment initiation.

CONCLUSIONS

Participants who experienced imAEs with STRIDE had a numerical improvement in OS versus those who did not, which was not observed for durvalumab. Long-term OS with STRIDE was observed regardless of imAEs. Most imAEs were low grade, manageable, and occurred in the first 3 months after treatment initiation. Results continue to support the benefits of STRIDE in a diverse population that reflects unresectable HCC globally.

Для цитирования: Lau George, Sangro Bruno, Cheng Ann-Lii, Kudo Masatoshi, Kelley Robin Kate, Tak Won Young, Gasbarrini Antonio, Reig Maria, Lim Ho Yeong, Tougeron David, De Toni Enrico N, Tam Vincent C, Mody Kabir, Gong Jun, Crysler Oxana V, Sukeepaisarnjaroen Wattana, Lipatov Oleg, Morimoto Manabu, Archambeaud Isabelle, Burgio Valentina, Phuong Le Thi Tuyet, Chao Yee, Peron Jean-Marie, Berres Marie-Luise, Ko Yoo-Joung, Ran Di, Makowsky Mallory, Negro Alejandra, Abou-Alfa Ghassan K. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.. Hepatology (Baltimore, Md.). 2025. DOI: 10.1097/hep.0000000000001385.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.